Biocon Biologics promotes Shreehas Tambe to Deputy CEO

Bengaluru: Biocon Biologics, a subsidiary of Biocon has recently announced that Mr Shreehas Tambe has been promoted to the position of Deputy Chief Executive Officer of Biocon Biologics Limited w.e.f. March 1, 2021.

A Biocon veteran, Shreehas joined Biocon in 1997 and has, since then, taken on positions of increasing responsibility. He has over 20 years of leadership experience in operational and strategic roles and has led large, diverse teams at R&D, Manufacturing and Projects & Engineering during his tenure.

Shreehas began his professional journey at Biocon as a Management Trainee starting out in the R&D department, where he led the design and development of a novel bioreactor, the PlaFractor, a unique solid state bioreactor that got Biocon its first U.S. patent and went on to win the National Award for the Best Technology of the Year in 2001.

Prior to becoming the Deputy CEO, Shreehas was the Chief Operating Officer and a key member of the Executive Leadership Team at Biocon Biologics.

Previously, as the Senior Vice President & Global Head of Biocon's Insulins business unit he was responsible for the P&L and expanding the Insulins portfolio across several geographies. He led the development, approval and launch of Insulin analogs in Japan and later in EU and U.S. The insulins franchise showed strong performance in emerging markets led by sales in Mexico, Malaysia and Latin America.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics, said: "I am delighted to welcome Shreehas Tambe in his new role as the Deputy CEO of Biocon Biologics. During his more than two decade-long career with Biocon, Shreehas has exhibited strong leadership in his diverse roles at R&D, Manufacturing and Projects & Engineering. Shreehas has also worked closely with Dr Arun Chandavarkar, Managing Director of Biocon Biologics, on formulating business strategies and achieving operational excellence. I believe the combination of Arun and Shreehas in their new roles along with the rest of the leadership team will enable Biocon Biologics to capitalize on the promising biosimilars opportunity to pursue its high growth trajectory."